Tharimmune Director Nancy Rickel Reports 50,000 Stock Options
Rhea-AI Filing Summary
Nancy Davis Rickel, a director of Tharimmune, Inc. (THAR), filed an initial Form 3 disclosing ownership of 50,000 stock options granted on 08/04/2025. The options are exercisable into common stock at an exercise price of $1.33 per share, with 25,000 shares vesting immediately and 25,000 vesting on 08/04/2026. The filing is signed by Ms. Rickel on 08/29/2025 and was filed as an individual Form 3.
Positive
- Director-level ownership disclosed: Nancy Davis Rickel reported beneficial ownership via a stock option grant of 50,000 options.
- Clear vesting schedule provided: 25,000 options vested on grant date and 25,000 vest on 08/04/2026, giving transparency on timing of potential ownership.
Negative
- None.
Insights
TL;DR: Director granted 50,000 options at $1.33, half vesting immediately, signaling initial equity stake without further context on dilution.
The Form 3 shows a director-level equity grant of 50,000 options exercisable into common stock at $1.33 per share, dated 08/04/2025. Immediate vesting of 25,000 shares provides present beneficial ownership, while the remaining 25,000 vest after one year, which phases the director's economic exposure. The disclosure is routine for initial insider reporting; materiality depends on total outstanding shares, which the filing does not provide.
TL;DR: Standard Section 16 disclosure for a director grant; documents ownership and vesting schedule but lacks context on grant approval.
The filing documents compliance with Section 16 reporting for an insider grant. It specifies the grant date, exercise price, and a clear vesting split (25,000 immediate; 25,000 on 08/04/2026). The form does not include information about board approval, option plan terms, or potential restrictions, so governance implications are limited to the disclosed facts.